Copyright
©The Author(s) 2015.
World J Gastrointest Pharmacol Ther. Nov 6, 2015; 6(4): 96-104
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.96
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.96
Functional dyspepsia1 |
Must include all of the following |
Persistent or recurrent pain or discomfort centered in the upper abdomen |
Pain or discomfort not relieved by defecation or associated with onset of a change in stool frequency or form |
Irritable bowel syndrome1 |
Must include all of the following |
Abdominal pain or discomfort associated with 2 or more of the following at least 25% of the time |
Improved by defecation |
Onset associated with a change in stool frequency |
Onset associated with a change in stool form |
Abdominal migraine |
Must include all of the following |
Paroxysmal episodes of intense, acute periumbilical pain lasting at least one hour |
Intervening periods of usual health lasting at least weeks |
Pain interferes with normal activity |
The pain is associated with at least two of the following |
Anorexia |
Nausea |
Vomiting |
Headache |
Photophobia |
Pallor |
Criteria must be fulfilled at least two times in the preceeding 12 mo |
Childhood functional abdominal pain1 |
Must include all of the following |
Episodic or continuous abdominal pain |
Does not meet criteria for another FGID |
Childhood functional abdominal pain syndrome |
Must include childhood FAP and at least 25% of the time with at least one of the following |
Some loss of daily function |
Additional somatic complaints such as headache, limb pain, or difficulty sleeping |
- Citation: Friesen CA, Schurman JV, Abdel-Rahman SM. Present state and future challenges in pediatric abdominal pain therapeutics research: Looking beyond the forest. World J Gastrointest Pharmacol Ther 2015; 6(4): 96-104
- URL: https://www.wjgnet.com/2150-5349/full/v6/i4/96.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v6.i4.96